Abrysvo, a respiratory syncytial virus (RSV) vaccine, was first approved in the United States in 2023 for the prevention of lower respiratory tract disease (LRTD) caused by RSV. Recent data presented at IDWeek 2026 highlights its efficacy in nursing home residents, a demographic particularly vulnerable to severe RSV outcomes.
This new evidence is significant as it may pave the way for re-vaccination strategies in older adults, who often experience diminished immune responses. The implications of these findings could influence regulatory discussions surrounding vaccination protocols, potentially leading to updated guidelines that prioritize booster doses for at-risk populations.
As the pharmaceutical industry continues to navigate the complexities of vaccine deployment and efficacy, the insights from IDWeek 2026 could be instrumental in shaping future clinical practices and public health policies aimed at safeguarding vulnerable groups against RSV.
Get started today with Solo access →
